CDMO (CDMO)

CDMO (CDMO) Healthcare & Pipeline Overview

Avid Bioservices, Inc. (CDMO) is a contract development and manufacturing organization specializing in biopharmaceutical drug substances. The company offers comprehensive services, including process development and commercial manufacturing, primarily serving biotechnology and biopharmaceutical clients, positioning it as a key partner in the outsourced biomanufacturing space.

What Is the Investment Thesis for CDMO?

Avid Bioservices presents a compelling investment case within the CDMO sector, driven by the increasing demand for outsourced biomanufacturing services. The company's focus on mammalian cell culture-derived drug substances positions it favorably in a market where monoclonal antibodies and recombinant proteins are significant growth drivers. While the company currently has a negative profit margin of -100.6% and a gross margin of 5.2%, strategic investments in capacity expansion and operational efficiencies could improve profitability. Key catalysts include securing new manufacturing contracts and successful regulatory approvals for client products. Potential risks include competition from larger CDMOs and fluctuations in demand for biopharmaceutical manufacturing services. Investors should monitor the company's ability to scale operations effectively and maintain high-quality standards to capitalize on industry growth.

Based on FMP financials and quantitative analysis

CDMO Key Highlights

• Avid Bioservices operates as a contract development and manufacturing organization (CDMO), capitalizing on the growing trend of biopharmaceutical companies outsourcing manufacturing.
• The company specializes in mammalian cell culture, a key technology for producing monoclonal antibodies and recombinant proteins.
• Avid Bioservices offers a comprehensive suite of services, from process development to commercial manufacturing, providing a one-stop solution for its clients.
• The company serves both biotechnology and biopharmaceutical industries, diversifying its revenue streams.
• Headquartered in Tustin, California, Avid Bioservices is strategically located in a region with a strong presence of biotechnology companies.

Who Are CDMO's Competitors?

CDMO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CDMO's Key Strengths?

• Specialized expertise in mammalian cell culture.
• Comprehensive service offerings from process development to commercial manufacturing.
• Strong relationships with biotechnology and biopharmaceutical clients.
• Proven track record of CGMP compliance.

What Are CDMO's Weaknesses?

• Negative profit margin.
• Reliance on a limited number of clients.
• Smaller scale compared to larger CDMOs.
• High capital expenditure requirements for capacity expansion.

What Could Drive CDMO Stock Higher?

• Securing new manufacturing contracts with biotechnology and biopharmaceutical companies.
• Successful regulatory approvals for client products manufactured by Avid Bioservices.
• Expansion of manufacturing capacity to meet increasing demand.
• Strategic partnerships and acquisitions to expand service offerings and geographic reach.

What Are the Key Risks for CDMO?

• Financial-distress signal — its Altman Z-Score of -0.58 sits in the distress zone (elevated bankruptcy risk).
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Insider selling — insiders were net sellers of roughly $1.4M recently.
• Competition from larger CDMOs with greater resources and capabilities.
• Fluctuations in demand for biopharmaceutical manufacturing services.
• Regulatory changes and compliance requirements that could increase costs.
• Reliance on a limited number of clients, posing a risk to revenue stability.
• Negative profit margin, requiring improvements in operational efficiency and cost management.

What Are the Growth Opportunities for CDMO?

• Expansion of Manufacturing Capacity: Avid Bioservices can capitalize on the increasing demand for biomanufacturing by expanding its production capacity. Investing in new facilities and equipment will enable the company to handle larger contracts and serve more clients. The biopharmaceutical CDMO market is expected to grow significantly, presenting a substantial opportunity for Avid Bioservices to increase its market share. Timeline: Ongoing.
• Strategic Partnerships and Acquisitions: Forming strategic alliances with biotechnology and pharmaceutical companies can provide Avid Bioservices with access to new technologies, markets, and clients. Acquisitions of smaller CDMOs with complementary capabilities can further expand the company's service offerings and geographic reach. The CDMO market is consolidating, making strategic partnerships and acquisitions a viable growth strategy. Timeline: Ongoing.
• Focus on High-Growth Therapeutic Areas: Targeting specific therapeutic areas with high growth potential, such as oncology and immunology, can drive revenue growth for Avid Bioservices. Developing specialized expertise and manufacturing capabilities in these areas will attract clients developing innovative therapies. The oncology and immunology markets are experiencing rapid growth, fueled by advancements in personalized medicine and targeted therapies. Timeline: Ongoing.
• Enhancement of Process Development Capabilities: Investing in advanced process development technologies and expertise can improve manufacturing efficiency, reduce costs, and accelerate timelines for clients. Offering innovative process development solutions will differentiate Avid Bioservices from its competitors and attract clients seeking cutting-edge technologies. The biopharmaceutical industry is constantly evolving, requiring CDMOs to stay ahead of the curve in process development. Timeline: Ongoing.
• Geographic Expansion: Expanding operations to new geographic regions, such as Europe and Asia, can provide access to new markets and clients. Establishing manufacturing facilities or partnerships in these regions will enable Avid Bioservices to serve a global client base. The biopharmaceutical industry is increasingly global, with significant growth opportunities in emerging markets. Timeline: Ongoing.

What Opportunities Does CDMO Have?

• Increasing demand for outsourced biomanufacturing.
• Expansion into new therapeutic areas.
• Strategic partnerships and acquisitions.
• Geographic expansion into new markets.

What Threats Does CDMO Face?

• Competition from larger CDMOs.
• Fluctuations in demand for biopharmaceutical manufacturing.
• Regulatory changes and compliance requirements.
• Technological advancements that could disrupt the industry.

What Are CDMO's Competitive Advantages?

• Specialized Expertise: Deep expertise in mammalian cell culture and biopharmaceutical manufacturing.
• Long-Term Relationships: Strong relationships with biotechnology and biopharmaceutical clients.
• Scalable Manufacturing: Ability to scale manufacturing from clinical to commercial production.
• Regulatory Compliance: Proven track record of CGMP compliance and regulatory approvals.

What Does CDMO Do?

Avid Bioservices, Inc., established in 1981 and headquartered in Tustin, California, operates as a contract development and manufacturing organization (CDMO) focused on providing comprehensive services for biopharmaceutical drug substances derived from mammalian cell culture. Originally incorporated as Peregrine Pharmaceuticals, Inc., the company rebranded as Avid Bioservices in January 2018 to better reflect its core business. Avid Bioservices offers a range of services, including CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, and regulatory submission and support. The company produces monoclonal antibodies and recombinant proteins, catering to the biotechnology and biopharmaceutical industries. Their process development services encompass upstream and downstream development and optimization, analytical methods development, testing, and characterization. Avid Bioservices plays a crucial role in supporting its clients from early-stage development through commercialization, offering scalable manufacturing solutions and expertise in complex biologics.

What Products and Services Does CDMO Offer?

• Provides contract development and manufacturing services to biotechnology and biopharmaceutical companies.
• Specializes in manufacturing biopharmaceutical drug substances derived from mammalian cell culture.
• Produces monoclonal antibodies and recombinant proteins.
• Offers CGMP clinical and commercial drug substance manufacturing.
• Provides bulk packaging, release and stability testing, and regulatory submission support.
• Offers upstream and downstream development and optimization services.
• Provides analytical methods development, testing, and characterization services.

How Does CDMO Make Money?

• Generates revenue by providing contract manufacturing services to biotechnology and biopharmaceutical companies.
• Charges fees for process development, clinical manufacturing, and commercial manufacturing services.
• Revenue is based on the scope and complexity of the manufacturing projects.
• Forms long-term partnerships with clients to provide ongoing manufacturing support.

What Industry Does CDMO Operate In?

Avid Bioservices operates within the rapidly expanding biopharmaceutical CDMO market. The industry is driven by the increasing complexity of biologics, the rising cost of in-house manufacturing, and the growing demand for specialized expertise. The global CDMO market is projected to reach significant growth in the coming years, fueled by advancements in biopharmaceutical research and development. Competition is intense, with several large players and smaller niche providers. Avid Bioservices differentiates itself through its focus on mammalian cell culture and its comprehensive service offerings, positioning it to capture a share of this expanding market.

Who Are CDMO's Key Customers?

• Biotechnology companies developing novel therapies.
• Biopharmaceutical companies seeking to outsource manufacturing.
• Companies requiring CGMP manufacturing for clinical trials.
• Companies requiring commercial-scale manufacturing for approved products.

Key Financial Metrics

Return on assets is -41.8%, showing how much profit it generates from its asset base. Its free cash flow yield is -2.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.47 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -17.8%, the inverse of the P/E and a quick read on earnings relative to price.

How CDMO Is Valued

CDMO carries a market capitalization of $798.90M, placing it in the small-cap category. Relative to its peer group, CDMO's quantitative score of 38/100 is below the peer average of 76/100.

F-Score 3/9Financial Health

CDMO's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -0.58 places it in the distress zone, a signal of elevated financial risk.

FY2027 estForward Outlook

Wall Street analysts project CDMO revenue of about $224.9M for fiscal 2027, with EPS near $0.18.

Net sellingInsider Activity

The most recent 12 insider filings for CDMO break down as 12 sales and 0 purchases. On net that is roughly 509K shares disposed (about $1.4M), a signal worth weighing alongside the fundamentals.

CDMO Financials

CDMO Latest News

CDMO Analyst Consensus

CDMO MoonshotScore

What Investors Ask About CDMO (CDMO) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources